Real-world evidence shows switching between etanercept products and etanercept biosimilars preserves efficacy and safety, ...

Spanish patients with various forms of inflammatory arthritis who started either etanercept or adalimumab were more likely to continue taking them if they were biosimilar versions rather than the ...

The biosimilar SB4 produced response rates equivalent to those associated with etanercept (ETN; Enbrel, Amgen) in patients with severe rheumatoid arthritis (RA) whose disease was not controlled by ...

Sandoz Group AG (OTC:SDZNY) (OTC:SDZXF) on Monday filed an antitrust lawsuit in the U.S. against Amgen, Inc. (NASDAQ:AMGN) for extending and entrenching the dominant market position of its blockbuster ...

The Supreme Court declined to review a petition filed by Novartis’ Sandoz unit that challenged two of Amgen’s patents on its blockbuster rheumatoid arthritis drug, Enbrel, meaning there won’t be a ...

Sandoz has filed an antitrust lawsuit in the United States against Amgen, for extending and entrenching the dominant market position of its blockbuster medicine, Enbrel (etanercept). The drug was ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

The rates of discontinuation due to inefficacy or adverse events for biosimilars and originators of etanercept and adalimumab were similar, according to an analysis of a prospective registry. The ...

Etanercept is a biologic medicine used to treat a range of disabling inflammatory diseases. Sandoz alleges that Amgen blocked competition from more cost-effective biosimilar competitors, including ...

A federal appeals court upheld two patents protecting Amgen’s blockbuster drug, Enbrel, against biosimilar competition, Biopharma Dive reported. Amgen has been in a yearslong legal battle with the ...

(RTTNews) - Sandoz (SDZNY) has initiated an antitrust lawsuit in the United States against Amgen, Inc. (AMGN), accusing the company of maintaining its dominant market position for the blockbuster drug ...